
News|Articles|February 8, 2024
mAb Characterization Process Innovations
Author(s)SCIEX
Earlier assessment of molecules provides valuable insights into the manufacturing developability of molecules, reducing the need for unnecessary experimentation. The Intabio ZT system has the potential to make in-depth characterization of biopharmaceutical product charge variants quicker and more efficient to meet demanding timelines during early-phase clinical development.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership
2
AstraZeneca Lupus Treatment Support in EU Opens Door for Self-Administration Options
3
Biopharma’s Digital Hopes Versus Actual Implementation
4
Check Your Knowledge: Patient-Centric Care Through Oral Liquid Delivery
5